# Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

> **NCT05758493** · PHASE2 · RECRUITING · sponsor: **Oregon Health and Science University** · enrollment: 150 (estimated)

## Conditions studied

- Amyloidosis
- Transthyretin Amyloidosis

## Interventions

- **DIAGNOSTIC_TEST:** 124I-Evuzamitide

## Key facts

- **NCT ID:** NCT05758493
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-10
- **Primary completion:** 2027-12-10
- **Final completion:** 2028-03-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758493, "Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05758493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*